No Detail Found!

Effect of Metformin Therapy on Clinical and Hormonal Indices of Patients with Polycystic Ovary Syndrome

Author(s)
SUMAIRA INAYAT Department, Northwest General Hospital and Research Center,Peshawar, Pakistan
HINA FAZAL KHATTAK Mian Rashid Hussain Shaheed Memorial Hospital,Pabbi, Pakistan
MOBASHARA GHULAM MUHAMMAD Mohtarma Benazir Bhutto Shaheed Medical College,Mirpur AJK, Pakistan
KOUSAR ROBEEN Mohammad College of Medicine, Muhammad Teaching Hospital,Peshawar, Pakistan
AFSHAN INAYAT Category D Badaber Hospital,Peshawar, Pakistan
FATIMA Mardan Medical Complex Mardan, Pakistan
Abstract
Objective: The main objective of this study is to determine the efficacy of metformin therapy on clinical and hormonal indices of patients with polycystic ovary syndrome. Study Design: Randomized control trial Place and Duration: Study was conducted at Obstetrics & Gynaecology department of Northwest General Hospital and Research Center, Peshawar and Mian Rashid Hussain Shaheed Memorial Hospital, Pabbi for duration of nine months from March 2020 to November 2020. Methods: Total 100 patients of polycystic ovary syndrome were presented in this study. Patients were aged between 18 to 45years. Patients detailed demographics including age, body mass index and socioeconomicstatus were recorded after taking informed written consent. Patients were divided into 2-groups, group I had 50 patients and received metformin (500 mg) three times a day and group II had 50 patients and received pioglitazone (30 mg) three times a day for 3months.Clinical (body weight, blood pressure (BP), and body mass index) and indices fasting blood sugar (FBS), serum triglyceride (TG), cholesterol, low-density lipoprotein, highdensity lipoprotein, insulin, testosterone, and dehydroepiandrosterone (DHEA) were measured before and after therapy. Complete data was analyzed by SPSS 22.0 version. Results: Mean age of the patients in group I was 29.18 ± 2.25 years with mean BMI 26.14 ± 8.86 kg/m2 and in group II mean age was 29.8 ± 2.52 years with mean BMI 27.64 ± 7.68 kg/m2.Significantly decrease in blood pressure (systolic 105.41±8.57, diastolic 67.19±8.9), hair loss 20 (40%),oligomenorrhea 23 (46%), body weight 74.45±9.72, waist circumference and dehydroepiandrosterone (DHEA) 2.35±0.67 and as compared to group II. Only triglycerides gave results of reduction in group II 115.39±64.11. Among both groups serum insulin, acne, menstrual disturbance and fasting blood sugar were controlled after treatment. Conclusion: We concluded in this study that use of metformin in patients with polycystic ovary syndrome resulted in to decrease clinical body weight, blood pressure (BP), body mass index and hormonal indices with reduction of serum insulin, acne, menstrual disturbance and fasting blood sugar but pioglitazone was an alternative effective and reliable method in PCOS patients.
Publication Details
Page(s) 1522-1525
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 15, Issue: 5, Year: 2021

Request the full text from PASTIC

Keywords
insulin resistance, polycystic ovary syndrome, metformin, Pioglitazone
0

Citations

0

Downloads

49

Views